EcoDrugPlus

Aldo-Keto Reductase Family 1 Member B1-Like

Ensembl ID : ENSLBEG00000004688
Gene Symbol: LOC109996322
3 Cross references
343 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B1-Like

Ensembl ID : ENSLBEG00000004645
Gene Symbol: LOC109996323
3 Cross references
345 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSLBEG00000021373
Gene Symbol: LOC109983380
3 Cross references
202 Possible Orthologues:

Alpha-2a Adrenergic Receptor-Like

Ensembl ID : ENSLBEG00000025036
Gene Symbol: LOC109998425
3 Cross references
176 Possible Orthologues:

Alpha-2c Adrenergic Receptor-Like

Ensembl ID : ENSLBEG00000012011
Gene Symbol: LOC109989582
3 Cross references
159 Possible Orthologues:

Alpha-2c Adrenergic Receptor-Like

Ensembl ID : ENSLBEG00000025939
Gene Symbol: LOC110005466
3 Cross references
159 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSLBEG00000011408
Gene Symbol: AOC1
3 Cross references
231 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSLBEG00000025008
Gene Symbol: APP
4 Cross references
203 Possible Orthologues:

Amyloid-Beta A4 Protein-Like

Ensembl ID : ENSLBEG00000000716
Gene Symbol: LOC109995134
3 Cross references
205 Possible Orthologues:

Androgen Receptor-Like

Ensembl ID : ENSLBEG00000014615
Gene Symbol: LOC109981070
2 Cross references
206 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSLBEG00000019531
Gene Symbol: AGTR1
3 Cross references
198 Possible Orthologues:

Apelin Receptor B-Like

Ensembl ID : ENSLBEG00000011908
Gene Symbol: LOC109993095
3 Cross references
171 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).